The study will be conducted in 3 parts:~Part I: Double-blind, placebo-controlled, randomized, multiple ascending dose study for 7 days of dosing with INDV-2000 in healthy volunteers.~Part II: Double-blind, placebo-controlled, randomized, multiple ascending dose study for 28 days of dosing with INDV-2000 in healthy volunteers.~Part III: This part is an open-label study in OUD treatment seeking individuals.
The primary objectives for the study are:~Part I and Part II: Assess safety and tolerability of repeated doses of INDV-2000 in healthy volunteers.~Part III: Assess the safety and tolerability of repeated doses of INDV-2000 administered alone and with SUBOXONE sublingual (SL) film in an opioid use disorder (OUD) treatment seeking population.